Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Clinical trial NCT05694884 · UNKNOWN
Trial details
- NCT number
- NCT05694884
- Sponsor
- ASLAN Pharmaceuticals
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-21
- Primary completion
- 2024-12-31
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.